Morishima, C.(2015). CITN11-02 interim trial results: Subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells. Journal for ImmunoTherapy of Cancer, 3(S2),
MLA ZitierstilMorishima, Chihiro. "CITN11-02 Interim Trial Results: Subcutaneous Administration of Recombinant Human IL-15 (rhIL-15) Is Associated With Expansion of Peripheral Blood CD56+ NK Cells and CD8+ T Cells". Journal for ImmunoTherapy of Cancer, 3.S2 ( 2015 )
Bitte überprüfen Sie diese Angaben auf Richtigkeit, bevor Sie sie in Ihre Arbeit aufnehmen.